Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 30, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Sean Dodge Maintained (CDMO) at Buy with Decreased Target to $22 on, Jun 30th, 2022
Sean Dodge of RBC Capital, Maintained "Avid Bioservices, Inc." (CDMO) at Buy with Decreased Target from $32 to $22 on, Jun 30th, 2022.
Sean has made no other calls on CDMO in the last 4 months.
There is 1 other peer that has a rating on CDMO. Out of the 1 peers that are also analyzing CDMO, 0 agree with Sean's Rating of Hold.
This is the rating of the analyst that currently disagrees with Sean
- Jacob Johnson of "Stephens & Co." Maintained at Buy with Decreased Target to $28 on, Wednesday, March 9th, 2022
